Wesfarmers shares experienced a notable upswing, reclaiming the A$90 mark following the release of strong annual financial results and a substantial capital return announcement. The diversified conglomerate’s performance reflects a positive outlook driven by consumer spending trends and strategic expansions, tempered by challenges in its lithium ventures.
Price Targets
The company’s shares closed at A$90.91 on the ASX today, a 2.53% increase, successfully surpassing the A$90 threshold. This movement contributes to a year-to-date gain of 27.29%, indicating strong market confidence in Wesfarmers’ diversified business model.
On August 27, 2025, Wesfarmers reported a 3.8% increase in annual net profit after tax (excluding significant items), reaching A$2.65 billion for the fiscal year ending June 30, 2025. This growth was largely fueled by robust performances in its retail divisions, with Bunnings recording a 3.8% profit increase and Kmart showing a 9.2% profit surge. Alongside the earnings report, Wesfarmers announced a A$1.7 billion capital return to shareholders, comprising a special distribution of A$1.50 per share and an increased final dividend of A$1.11 per share, up from A$1.07 the previous year. These returns were financed through recent asset sales, including the divestment of its residual interest in Coles.
Wesfarmers has also benefited from a resurgence in consumer spending, driven by easing inflation and interest rates, including three rate cuts by the Reserve Bank of Australia this year. According to Reuters, CEO Rob Scott noted increased shopper confidence and spending, particularly benefiting Bunnings’ home improvement products and Kmart’s Anko brand.
The company is actively expanding its healthcare division, Wesfarmers Health, following the acquisition of Australian Pharmaceutical Industries (API) in March 2022. Strategic moves include the acquisition of InstantScripts in June 2023 for A$135 million and the Pharmacy 4 Less Group in June 2025, bolstering its presence in the healthcare and beauty sectors with ventures like the Atomica pilot beauty store concept launched in late 2024.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
However, Wesfarmers’ ventures into the lithium market have encountered headwinds due to prevailing low lithium prices. The company acknowledged that its lithium operations would be unprofitable under current market conditions. Scott stated that stalled projects by other producers might lead to supply tightening and eventual price recovery.
Analyst Summary: Bull and Bear Cases
Bull Case:
- Strong retail performance drives earnings growth.
- Capital returns and dividends boost shareholder value.
- Healthcare and beauty sector expansion diversifies revenue.
Bear Case:
- Lithium operations unprofitable at current prices.
- Consumer spending resurgence could be temporary.
- Diversified model adds complexity and risk.
The market’s response to Wesfarmers’ announcements has been largely positive, reflecting confidence in the company’s diversified strategy and strong retail performance. However, the lithium challenges introduce an element of caution, potentially tempering future gains.
